Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Reproductive Health Services

 
In compliance with the decisions of the International Conference on Population and Development in 1994 on behalf of the Government of Lebanon, the “Reproductive Health Program” was established at the Ministry of Public Health and supported by the United Nations Population Fund (UNFPA) under the umbrella of primary health care with a clear strategy between 1998 and 2001. The program is still ongoing through its integration within the primary health care department.

The Ministry of Public Health / Primary Health Care Department in collaboration with UNFPA provides various services regarding reproductive health and family planning in agreement with the joint annual work plan signed between the two parties.

The health services can be summarized in the following categories:
  • Family planning
  • Safe motherhood and Newborn Health
  • Diagnostic & Preventive Check-ups
  • Screening for Reproductive system diseases and reproductive tract cancers

I. Reproductive Health Services
The primary health care department provides preventive services in order to improve the health of the family (women, children, youth and men) through:
  • Providing reproductive health medications and supplies through PHC centers, including 57 health centers / clinics outside the primary health care network, and providing reproductive health services to the displaced in order to improve women's health and prevent unwanted pregnancies.
  • Delivering reproductive health information to beneficiaries through awareness and education programs which are provided by the primary health care centers within and outside the centers.
  • Providing equipment that enables early detection of reproductive system diseases (early detection of breast cancer, cervical cancer).
  • Encouraging pregnant women to receive a minimum of 4 visits during pregnancy and one postnatal visit.
  • Developing the capacity of service providers in primary health care centers based on the clinical protocols for reproductive health.
  • Preparing governmental hospitals to receive emergency obstetric cases.
  •  Equipping governmental hospitals to receive high-risk pregnancies.
  •  Capacity building of service providers to deal with survivors of sexual violence and refer them to relevant associations.
  • Capacity building of service providers of provision of equipment for primary health care centers and hospitals to address cases of rape and refer survivors to the relevant associations.
 

II. Antenatal and Postnatal Care Services:
The primary health care department offers as well antenatal and postnatal care services for pregnant Lebanese and non-Lebanese women across Lebanon as part of the reproductive health services. These services were supported by the formulation of the ‘’Service Delivery Guidelines’’, which were followed by consecutive training for primary health care (PHC) centers’ staff across Lebanon upon implementation.

The antenatal and postnatal care services offered by the PHC centers consist of the following:
All pregnant women visiting the centers should receive:
  1.  Minimum of 4 antenatal care services
  2.  2 Echography during pregnancy
  3.  1 postnatal visit
  4.  Coverage of vaccination for newborn of followed up mothers (according to the National Vaccination Calendar)
  5.  Provision of Reproductive Health drugs and supplies to all PHC centers, in addition to 64 Reproductive Health dispensaries supported by International NGOs to serve the displaced Syrians.
 

III. Service Delivery Guidelines for Reporoductive Health Care:
MoPH with the support of UNFPA and in collaboration with the Lebanese Society of Obstetrics & Gynecology (LSOG) launched " The Revised Version of the Service Delivery Guidelines for Reproductive Health" in June 2015, which aimed at improving the knowledge and skills of service providers, in order to ensure the provision of reproductive health services that meet women's, men's and youth's needs in Lebanon.

Accordingly, the first phase of training took place from July to September, with 275 physicians and health care workers, including: 160 paramedical specialties, 88 medical and 27 humanitarian actors.

The training aims to improve the knowledge, skills and confidence of health workers to ensure that reproductive health needs of women, men adults and youth are met in normal setting and in the case of crises.
 
IV. Project Reports:
    1
ATC Name B/G Ingredients Dosage Form Price
B02BD06 HAEMATE P BioHuman Von Willebrand Factor - 1200IU, Blood Coagulation Factor VIII - 500IU Injectable lyophilised powder for solution+diluent L.L
B02BD06 HAEMATE P BioHuman Von Willebrand Factor - 1200IU, Blood Coagulation Factor VIII - 500IU Injectable lyophilised powder for solution+diluent 35,032,787 L.L
B02BB01 HAEMOCOMPLETTAN P BioHuman Fibrinogen, human - 1g 1g Injectable powder for solution 41,515,083 L.L
B02BB01 HAEMOCOMPLETTAN P BioHuman Fibrinogen, human - 1g 1g Injectable powder for solution L.L
D11AX01 HAIRGAINE 5 G Minoxidil - 5% 5% Solution 1,963,354 L.L
D11AX01 HAIRGROW G Minoxidil - 5% 5% Solution 1,061,636 L.L
L01XX41 HALAVEN B Eribulin mesylate - 0.88mg/2ml 0.88mg/2ml Injectable solution L.L
L01XX41 HALAVEN B Eribulin mesylate - 0.88mg/2ml 0.88mg/2ml Injectable solution 18,792,549 L.L
N05AD01 HALOPERIDOL G Haloperidol - 5mg 5mg Tablet 276,448 L.L
N05AD01 HALOPERIDOL G Haloperidol - 2mg 2mg Tablet 252,130 L.L
N05AD01 HALOPERIDOL G Haloperidol - 10mg 10mg Tablet 339,160 L.L
N05AD01 HALOPERIDOL G Haloperidol - 20mg 20mg Tablet 339,160 L.L
N03AF02 HARMONIE G Oxcarbazepine - 300mg 300mg Tablet, film coated 889,496 L.L
J07BC02 HAVRIX '1440' B Hepatitis A, inactivated, whole virus - 1,440 ELISA units/ml 1,440 ELISA units/ml Injectable suspension 2,215,996 L.L
J07BC02 HAVRIX JUNIOR 720 B Hepatitis A, inactivated, whole virus - 720 ELISA units/0.5ml 720 ELISA units/0.5ml Injectable suspension 1,491,665 L.L
L01BC05 HAXANIT G Gemcitabine (HCl) - 200mg 200mg Injectable lyophilised powder 1,411,035 L.L
L01BC05 HAXANIT G Gemcitabine (HCl) - 1g 1g Injectable lyophilised powder 6,829,408 L.L
D03AX HEALIN B G ?-sitosterol - 0.25% 0.25% Ointment 849,820 L.L
J07BC02 HEALIVE-HEPATITIS A VACCINE (HUMAN DIPLOID CELL) INACTIVATED BioTech Hepatitis A, inactivated antigen (TZ84 Strain), human diploid cell - 0.5ml/dose 0.5ml/dose Injectable suspension 1,777,904 L.L
J07BC02 HEALIVE-HEPATITIS A VACCINE (HUMAN DIPLOID CELL) INACTIVATED BioTech Hepatitis A, inactivated antigen (TZ84 Strain), human diploid cell - 1ml/dose 0.5ml/dose Injectable suspension 2,257,655 L.L
R05CA12 HEDECTON COUGH G Ivy leaf soft extract - 40mg/5ml Syrup 467,657 L.L
R05CA12 HEDERAL G Dried Ivy leaf extract (Hedera Helix) - 99mg/5ml 99mg/5ml Drops solution 384,339 L.L
R05CA12 HEDERAL G Dried Ivy leaf extract - 37mg/5ml 37mg/5ml Syrup 309,084 L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 10,000IU 10,000IU Injectable freeze dried substance+diluent L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 40,000IU 40,000IU Injectable freeze dried powder + diluent L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 4,000IU 4,000IU Injectable freeze dried substance+diluent 940,690 L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 4,000IU 4,000IU Injectable freeze dried substance+diluent 33,852,747 L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 10,000IU 10,000IU Injectable freeze dried substance+diluent 2,687,685 L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 20,000IU 20,000IU Injectable freeze dried powder + diluent 5,438,531 L.L
B03XA01 HEMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 40,000IU 40,000IU Injectable freeze dried powder + diluent 6,316,060 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026